What is the standard of care for metastatic Prostate Cancer according to NCCN guidelines

Standard of Care for Metastatic Prostate Cancer (NCCN Guidelines)

The treatment approach for metastatic prostate cancer depends on several key factors, including whether the cancer is castration-sensitive (responds to hormone therapy) or castration-resistant (has progressed despite hormone therapy), and the volume of disease present.

STEP 1: HOW DOCTORS THINK ABOUT METASTATIC PROSTATE CANCER

According to the NCCN Guidelines Version 2.2026, oncologists evaluate metastatic prostate cancer by:

1. Determining disease burden - Is it low-volume (fewer metastases) or high-volume (extensive spread)?
2. Assessing hormone sensitivity - Does the cancer respond to androgen deprivation therapy (ADT)?
3. Measuring PSA doubling time (PSADT) - How quickly PSA levels are rising
4. Evaluating testosterone levels - Ensuring castrate levels (<50 ng/dL) are maintained
5. Testing for genetic mutations - Looking for DNA repair defects and other biomarkers that guide treatment selection

STEP 2: GENERAL TREATMENT APPROACHES

For Castration-Sensitive Metastatic Disease (mCSPC)

First-line combination therapy is strongly recommended:

According to NCCN Guidelines, ADT (androgen deprivation therapy) combined with additional systemic therapy is the standard approach. The guidelines note that "ADT monotherapy in metastatic castration-sensitive disease is discouraged unless there are clear contraindications to combination therapy."

Combination options typically include:

• ADT + Docetaxel (chemotherapy)
• ADT + Abiraterone (hormone therapy)
• ADT + Apalutamide (hormone therapy)
• ADT + Enzalutamide (hormone therapy)

Special consideration for disease burden:

• Low-volume disease (≤4 bone metastases without visceral involvement): Radiation therapy to the primary tumor may be recommended alongside systemic therapy
• High-volume disease (≥4 bone lesions or visceral metastases): Systemic therapy is primary; radiation to primary tumor can be considered in select patients

For Castration-Resistant Metastatic Disease (mCRPC)

When cancer progresses despite castrate testosterone levels, the NCCN Guidelines recommend:

Preferred Category 1 options (highest level of evidence):

• Apalutamide
• Darolutamide
• Enzalutamide

Other recommended secondary hormone therapies may be considered based on individual circumstances.

Additional supportive care:

• Bone antiresorptive therapy (denosumab or zoledronic acid) if bone metastases are present
• Palliative radiation for painful bone metastases
• PSA and imaging monitoring every 3-6 months

Biomarker-Directed Therapy

The NCCN Guidelines emphasize testing for:

• Homologous recombination repair (HRR) mutations - May indicate benefit from PARP inhibitors
• Microsatellite instability (MSI) or mismatch repair deficiency (dMMR)
• Tumor mutational burden (TMB)

These genetic findings can open additional treatment pathways beyond standard hormone therapies.

STEP 3: QUESTIONS TO ASK YOUR ONCOLOGIST

Since your specific situation requires your doctor's complete evaluation, here are critical questions to discuss:

1. "Based on my cancer's stage and genetic testing, is my disease castration-sensitive or castration-resistant?" - This fundamentally determines your treatment pathway.

2. "What is my disease burden (low-volume vs. high-volume), and how does that affect my treatment recommendations?" - Volume of disease significantly impacts whether radiation or other local therapies are recommended.

3. "Do I have any genetic mutations (HRR, MSI, TMB) that would make me eligible for targeted therapies like PARP inhibitors?" - These biomarkers can dramatically change treatment options.

4. "What combination therapy do you recommend for me, and what are the expected benefits and side effects?" - Understanding the rationale for YOUR specific regimen is essential.

5. "How will we monitor my response to treatment, and what PSA levels or imaging findings would indicate we need to change approaches?" - Clear monitoring plans help you understand what to expect.

STEP 4: IMPORTANT BOUNDARY

Your oncologist will determine the most appropriate approach for YOUR specific case based on your complete clinical picture, including your age, overall health, genetic test results, disease extent, and personal preferences regarding quality of life.

The NCCN Guidelines provide the framework, but your doctor makes the final determination about which specific treatment is best for you.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.